Display options
Cite
Perez-Hernandez J, Chiurchiù V, Perruche S, et al. Regulation of T-Cell Immune Responses by Pro-Resolving Lipid Mediators. Front Immunol. 2021;12:768133doi: 10.3389/fimmu.2021.768133.
Perez-Hernandez, J., Chiurchiù, V., Perruche, S., & You, S. (2021). Regulation of T-Cell Immune Responses by Pro-Resolving Lipid Mediators. Frontiers in immunology, 12768133. https://doi.org/10.3389/fimmu.2021.768133
Perez-Hernandez, Javier, et al. "Regulation of T-Cell Immune Responses by Pro-Resolving Lipid Mediators." Frontiers in immunology vol. 12 (2021): 768133. doi: https://doi.org/10.3389/fimmu.2021.768133
Perez-Hernandez J, Chiurchiù V, Perruche S, You S. Regulation of T-Cell Immune Responses by Pro-Resolving Lipid Mediators. Front Immunol. 2021 Nov 16;12:768133. doi: 10.3389/fimmu.2021.768133. eCollection 2021. PMID: 34868025; PMCID: PMC8635229.
Copy Download .nbib Format: NLM
Share it on

Front Immunol. 2021 Nov 16;12:768133. doi: 10.3389/fimmu.2021.768133. eCollection 2021.

Regulation of T-Cell Immune Responses by Pro-Resolving Lipid Mediators.

Frontiers in immunology

Javier Perez-Hernandez, Valerio Chiurchiù, Sylvain Perruche, Sylvaine You

Affiliations

  1. Université de Paris, Institut Cochin, CNRS, Institut National de la Santé et de le Recherche Médicale (INSERM), Paris, France.
  2. Departament of Nutrition and Health, Valencian International University (VIU), Valencia, Spain.
  3. Institute of Translational Pharmacology, National Research Council, Rome, Italy.
  4. Laboratory of Resolution of Neuroinflammation, European Center for Brain Research, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Santa Lucia Foundation, Rome, Italy.
  5. Université de Bourgogne Franche-Comté, INSERM, Etablissement Français du Sang (EFS) Bourgogne-Franche Comté (BFC), Unité Mixte de Recherche (UMR)1098 Research on Interaction between Graft, Host and Tumor (RIGHT), Interactions Hôte Greffon-Tumeur/Ingénierie Cellulaire et Génique, Fédération Hospitalo-Universitaire Integrated Center for REsearch in inflammatory diseASes (InCREASe), Besançon, France.
  6. MED'INN'Pharma, Besançon, France.

PMID: 34868025 PMCID: PMC8635229 DOI: 10.3389/fimmu.2021.768133

Abstract

Both the initiation and the resolution of inflammatory responses are governed by the sequential activation, migration, and control/suppression of immune cells at the site of injury. Bioactive lipids play a major role in the fine-tuning of this dynamic process in a timely manner. During inflammation and its resolution, polymorphonuclear cells (PMNs) and macrophages switch from producing pro-inflammatory prostaglandins and leukotrienes to specialized pro-resolving lipid mediators (SPMs), namely, lipoxins, resolvins, protectins, and maresins, which are operative at the local level to limit further inflammation and tissue injury and restore homeostasis. Accumulating evidences expand now the role and actions of these lipid mediators from innate to adaptive immunity. In particular, SPMs have been shown to contribute to the control of chronic inflammation, and alterations in their production and/or function have been associated with the persistence of several pathological conditions, including autoimmunity, in human and experimental models. In this review, we focus on the impact of pro-resolving lipids on T cells through their ability to modulate T-cell responses. In particular, the effects of the different families of SPMs to restrain effector T-cell functions while promoting regulatory T cells will be reviewed, along with the underlying mechanisms. Furthermore, the emerging concept of SPMs as new biological markers for disease diagnostic and progression and as putative therapeutic tools to regulate the development and magnitude of inflammatory and autoimmune diseases is discussed.

Copyright © 2021 Perez-Hernandez, Chiurchiù, Perruche and You.

Keywords: T cell; adaptive immunity; autoimmunity; chronic inflammation; resolution; specialized pro-resolving lipid mediators (SPMs); therapy

Conflict of interest statement

SP is the CEO and shareholder of MED’INN’Pharma, which develops pro-resolutive drug candidates. The remaining authors declare that the research was conducted in the absence of any commercial or financ

References

  1. Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):14983-8 - PubMed
  2. Biochem Biophys Res Commun. 2008 Mar 7;367(2):509-15 - PubMed
  3. Nature. 2014 Jun 5;510(7503):92-101 - PubMed
  4. Eur J Immunol. 2016 Jan;46(1):81-91 - PubMed
  5. Invest Ophthalmol Vis Sci. 2018 Aug 1;59(10):3911-3919 - PubMed
  6. Int Immunopharmacol. 2011 Jan;11(1):55-66 - PubMed
  7. Pharmacol Res. 2019 Nov;149:104456 - PubMed
  8. J Ocul Pharmacol Ther. 2010 Oct;26(5):431-9 - PubMed
  9. Immunity. 2014 Mar 20;40(3):315-27 - PubMed
  10. PLoS One. 2017 Jun 12;12(6):e0179184 - PubMed
  11. Sci Adv. 2021 Apr 2;7(14): - PubMed
  12. Circ Res. 2020 Jul 17;127(3):335-353 - PubMed
  13. Front Immunol. 2021 Sep 13;12:704163 - PubMed
  14. J Biol Chem. 2006 Aug 11;281(32):22847-54 - PubMed
  15. Elife. 2020 Mar 02;9: - PubMed
  16. J Immunol. 2007 Jan 1;178(1):496-502 - PubMed
  17. Mol Aspects Med. 2017 Dec;58:1-11 - PubMed
  18. Front Cell Neurosci. 2021 Apr 26;15:673549 - PubMed
  19. J Immunol. 2013 Sep 15;191(6):3462-70 - PubMed
  20. Int Immunopharmacol. 2012 Dec;14(4):384-91 - PubMed
  21. Immunol Lett. 2017 Nov;191:63-72 - PubMed
  22. Int Immunopharmacol. 2021 Sep;98:107883 - PubMed
  23. Oncol Rep. 2016 Jan;35(1):307-17 - PubMed
  24. Br J Pharmacol. 2010 May;160(2):292-310 - PubMed
  25. Nat Immunol. 2003 Oct;4(10):982-90 - PubMed
  26. Front Immunol. 2018 Jan 29;9:38 - PubMed
  27. Immunity. 2018 Oct 16;49(4):666-677.e6 - PubMed
  28. J Allergy Clin Immunol. 2019 Feb;143(2):631-643 - PubMed
  29. Invest Ophthalmol Vis Sci. 2009 Aug;50(8):3613-20 - PubMed
  30. Mol Aspects Med. 2020 Aug;74:100894 - PubMed
  31. Mucosal Immunol. 2019 Jan;12(1):145-153 - PubMed
  32. Front Immunol. 2021 May 03;12:664756 - PubMed
  33. JCI Insight. 2017 Feb 9;2(3):e88588 - PubMed
  34. Life Sci. 2020 Aug 1;254:117773 - PubMed
  35. J Am Heart Assoc. 2020 Aug 4;9(15):e016113 - PubMed
  36. J Immunol. 2012 Aug 15;189(4):1983-91 - PubMed
  37. Front Immunol. 2021 Mar 17;12:637983 - PubMed
  38. Cell Death Differ. 2021 Nov;28(11):3140-3160 - PubMed
  39. J Immunol. 2003 Jun 15;170(12):6266-72 - PubMed
  40. Blood. 2006 Jan 15;107(2):444-53 - PubMed
  41. FASEB J. 2018 Oct;32(10):5413-5425 - PubMed
  42. Immunol Lett. 2017 Jan;181:51-57 - PubMed
  43. J Immunol. 2005 Apr 15;174(8):4979-84 - PubMed
  44. J Immunol. 2015 Oct 1;195(7):3086-99 - PubMed
  45. Front Immunol. 2019 Sep 27;10:2241 - PubMed
  46. J Neurosci. 2016 Sep 14;36(37):9590-603 - PubMed
  47. J Immunol. 2011 Feb 1;186(3):1735-46 - PubMed
  48. J Immunol. 2006 Mar 1;176(5):3157-64 - PubMed
  49. J Infect Dis. 2017 Feb 1;215(3):431-439 - PubMed
  50. Mucosal Immunol. 2018 Nov;11(6):1674-1683 - PubMed
  51. Front Physiol. 2020 Apr 03;11:285 - PubMed
  52. Immunol Rev. 2014 May;259(1):40-59 - PubMed
  53. Cell. 2010 Mar 5;140(5):619-30 - PubMed
  54. Immunol Cell Biol. 2015 May-Jun;93(5):472-9 - PubMed
  55. Invest Ophthalmol Vis Sci. 2014 Aug 21;55(9):5944-51 - PubMed
  56. FASEB J. 2019 Jan;33(1):909-916 - PubMed
  57. Mol Aspects Med. 2017 Dec;58:114-129 - PubMed
  58. Sci Rep. 2018 Aug 8;8(1):11873 - PubMed
  59. Nat Immunol. 2003 Oct;4(10):965-73 - PubMed
  60. Ann Allergy Asthma Immunol. 2014 Mar;112(3):211-216.e1 - PubMed
  61. Cell. 2010 Mar 19;140(6):871-82 - PubMed
  62. Adv Drug Deliv Rev. 2020;159:133-169 - PubMed
  63. Sci Transl Med. 2016 Aug 24;8(353):353ra111 - PubMed
  64. J Leukoc Biol. 2017 Nov;102(5):1159-1171 - PubMed
  65. Proc Natl Acad Sci U S A. 2010 Jul 6;107(27):12233-8 - PubMed
  66. Immunology. 2015 Sep;146(1):50-8 - PubMed
  67. J Exp Med. 2015 Oct 19;212(11):1921-30 - PubMed
  68. J Biol Chem. 2015 Dec 25;290(52):30697-712 - PubMed
  69. J Immunol. 2015 Feb 1;194(3):863-7 - PubMed
  70. Mediators Inflamm. 2012;2012:318621 - PubMed
  71. Front Immunol. 2021 May 19;12:668760 - PubMed
  72. Invest Ophthalmol Vis Sci. 2013 Sep 17;54(9):6269-79 - PubMed
  73. Nat Immunol. 2008 Aug;9(8):873-9 - PubMed
  74. Front Immunol. 2018 Apr 25;9:785 - PubMed
  75. J Clin Invest. 2018 Jul 2;128(7):2657-2669 - PubMed
  76. Front Microbiol. 2020 Oct 30;11:587725 - PubMed
  77. J Immunol. 2016 Sep 15;197(6):2362-8 - PubMed
  78. Pharmacotherapy. 2021 Aug 24;: - PubMed
  79. J Exp Med. 2005 Jul 4;202(1):97-110 - PubMed
  80. Am J Physiol Lung Cell Mol Physiol. 2015 May 1;308(9):L904-11 - PubMed
  81. J Immunol. 2012 Jul 15;189(2):1036-42 - PubMed
  82. Int J Exp Pathol. 2007 Apr;88(2):85-94 - PubMed
  83. J Clin Invest. 2019 Dec 2;129(12):5294-5311 - PubMed
  84. J Immunol. 2005 Aug 1;175(3):1483-90 - PubMed
  85. Front Immunol. 2014 Aug 01;5:354 - PubMed
  86. Sci Rep. 2018 Apr 3;8(1):5522 - PubMed
  87. J Immunol. 2007 Mar 15;178(6):3912-7 - PubMed
  88. Cell Rep. 2021 Jun 1;35(9):109201 - PubMed
  89. Eur J Immunol. 2014 Feb;44(2):357-69 - PubMed
  90. Nutrients. 2021 Jul 15;13(7): - PubMed
  91. Nat Commun. 2013;4:1685 - PubMed
  92. Prostaglandins Leukot Essent Fatty Acids. 2009 Apr;80(4):195-200 - PubMed
  93. Nature. 2015 Jul 9;523(7559):221-5 - PubMed
  94. Cell Death Dis. 2021 Mar 15;12(3):280 - PubMed
  95. Ann Rheum Dis. 2018 Nov;77(11):1644-1652 - PubMed
  96. Biochem Biophys Res Commun. 2010 Sep 10;400(1):128-33 - PubMed
  97. J Clin Invest. 2018 Aug 1;128(8):3568-3582 - PubMed
  98. J Immunol. 2008 Oct 1;181(7):4534-44 - PubMed
  99. J Biol Chem. 2005 Dec 30;280(52):43079-86 - PubMed
  100. Am J Transl Res. 2016 Jun 15;8(6):2758-66 - PubMed
  101. Haematologica. 2020 Aug;105(8):2056-2070 - PubMed
  102. Rheumatology (Oxford). 2019 Jul 1;58(7):1285-1292 - PubMed
  103. Mediators Inflamm. 2015;2015:149381 - PubMed
  104. FASEB J. 2021 Jun;35(6):e21666 - PubMed

Publication Types